Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Molten Ventures PLC Share Issue/Capital Change 2020

Aug 12, 2020

4951_nav_2020-08-12_cf1de545-9a23-47eb-ad46-38c2a23c1619.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 8450V

Draper Esprit PLC

12 August 2020

DRAPER ESPRIT PLC

("Draper Esprit" or the "Company")

Issue of Equity for Option Exercise under 2016 Company Share Option Plan

Draper Esprit PLC (AIM: GROW, ESM: GRW), a leading venture capital firm involved in the creation, funding and development of high-growth digital technology businesses, announces that on 7 August 2020, it approved the allotment of 30,000 new ordinary shares of 1p each in the Company (the "Ordinary Shares") pursuant to the exercise of share options by an employee under the 2016 Company Share Option Plan ("CSOP").

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and Euronext Growth and it is expected that admission will take place on 17 August 2020. The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following this allotment, the total issued share capital of the Company will increase to 118,948,124 Ordinary Shares.

Enquiries

Draper Esprit plc

Martin Davis (Chief Executive Officer)

Ben Wilkinson (Chief Financial Officer)
+44 (0)20 7931 8800
Numis Securities

Nominated Adviser & Joint Broker

Richard Thomas

Jamie Loughborough
+44 (0)20 7260 1000
Goodbody Stockbrokers

Euronext Growth Adviser & Joint Broker

Don Harrington

Charlotte Craigie

Dearbhla Gallagher
+44 (0) 20 3841 6202
Powerscourt

Public relations

James White

Elly Williamson

Jessica Hodgson
+44 (0)20 7250 1446

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IOEKKDBPCBKDPFD